StreetInsider.com News Articles

Abbott (ABT) Declares $0.63 Quarterly Dividend; 2.5% Yield

Thu, 17 Sep 2026 12:45:13 -0400

Abbott (NYSE: ABT) declared a quarterly dividend of $0.63 per share, or $2.52 annualized.

The dividend will be payable on November 16, 2026, to stockholders of record on October 15, 2026, with an ex-dividend date of October 14, 2026.

The annual yield on the dividend is 2.5 percent.

For a dividend history and other dividend-related data on Abbott (ABT) click here.

Abbott declares 411th consecutive quarterly dividend

Thu, 17 Sep 2026 12:43:00 -0400

ABBOTT PARK, Ill., Sept. 17, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share.

This marks the 411^th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov. 16, 2026, to shareholders of record at the close of business on Oct. 15, 2026.

Abbott declares 411th consecutive quarterly dividend

Thu, 17 Sep 2026 12:43:00 -0400

ABBOTT PARK, Ill., Sept. 17, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share.

This marks the 411^th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov. 16, 2026, to shareholders of record at the close of business on Oct. 15, 2026.

Abbott to pay $385 million to settle DOJ infant formula claims

Mon, 14 Sep 2026 12:42:09 -0400

Abbott (NYSE: ABT) has agreed to pay $385 million to resolve claims brought by the U.S. Department of Justice, several state attorneys general, and certain private parties related to the company's manufacturing practices and 2022 recall of powdered infant formula produced at its Sturgis, Mich., facility.

According to a statement from the company, the settlement does not constitute a finding of fault or liability. The Justice Department has also closed its criminal investigation into the matter, the company said.

The 2022 recall prompted a significant shortage of infant formula in the United States. Abbott has maintained that no unopened, distributed Abbott infant

Abbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recall

Mon, 14 Sep 2026 11:52:00 -0400

Settlement does not represent any finding of fault or liability
As the government has previously indicated, it has closed its criminal investigation on this matter
Tests by government regulators of

Abbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recall

Mon, 14 Sep 2026 11:52:00 -0400

Settlement does not represent any finding of fault or liability
As the government has previously indicated, it has closed its criminal investigation on this matter
Tests by government regulators of

Abbott to pay $385M to settle contaminated infant formula allegations

Mon, 14 Sep 2026 11:43:55 -0400

Abbott Laboratories has agreed to pay $384,999,040 to resolve allegations that it caused false claims to be submitted to federal and state programs related to the manufacture of powder infant formula and nutritional therapy products at its facilities in Sturgis, Michigan, and Casa Grande, Arizona, between Jan. 1, 2018, and Dec. 31, 2022, according to a statement from the U.S. Department of Justice.

Under the civil settlement, Abbott will pay $348,700,868 to the United States to resolve False Claims Act allegations and an additional $36,298,172 to certain states for claims related to their Medicaid and WIC programs.

The U.S. government alleged that

Abbott to pay $385M to settle contaminated infant formula allegations

Mon, 14 Sep 2026 11:43:55 -0400

The U.S. government alleged that

Abbott wins FDA approval for dual-energy AFib ablation catheter

Tue, 08 Sep 2026 08:01:09 -0400

Abbott (NYSE: ABT) received U.S. Food and Drug Administration approval for its TactiFlex Duo Ablation Catheter, Sensor Enabled, a device designed to treat patients with atrial fibrillation, according to a company press release dated Sept. 8, 2026.

The catheter combines two energy modalities — pulsed field ablation and radiofrequency energy — in a single device, allowing physicians to use either or both during a procedure. Abbott said it plans to begin broader commercial rollout across the U.S. in the coming weeks.

The FDA approval was based on results from Abbott's FlexPulse IDE study. Data from the study were presented at the European

Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms

Tue, 08 Sep 2026 08:00:00 -0400

Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single catheter to treat complex atrial fibrillation (AFib) cases
Strong clinical evidence demonstrates the device's high rates of safety and effectiveness in treating AFib patients
FDA approval of TactiFlex Duo strengthens Abbott's expanding PFA portfolio following recent cardiac ablation approvals in the U.S., Europe, Asia and Latin America

ABBOTT PARK, Ill., Sept. 8, 2026 /PRNewswire/ -- Abbott, the global healthcare

Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms

Tue, 08 Sep 2026 08:00:00 -0400

Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single catheter to treat complex atrial fibrillation (AFib) cases
Strong clinical evidence demonstrates the device's high rates of safety and effectiveness in treating AFib patients
FDA approval of TactiFlex Duo strengthens Abbott's expanding PFA portfolio following recent cardiac ablation approvals in the U.S., Europe, Asia and Latin America

ABBOTT PARK, Ill., Sept. 8, 2026 /PRNewswire/ -- Abbott, the global healthcare

Form 4 ABBOTT LABORATORIES For: Sep 01 Filed by: MCCOY JOHN A. JR.

Thu, 03 Sep 2026 18:11:00 -0400

si-local-file:///var/storage/secattach/20260903/27026280.html

Form 4 ABBOTT LABORATORIES For: Sep 01 Filed by: Boudreau Philip P

Thu, 03 Sep 2026 18:02:00 -0400

si-local-file:///var/storage/secattach/20260903/27026248.html

Form 144 ABBOTT LABORATORIES Filed by: MCCOY JOHN A. JR.

Wed, 02 Sep 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20260902/27020170.html

Form 144 ABBOTT LABORATORIES Filed by: Ford Robert B

Mon, 31 Aug 2026 12:53:00 -0400

si-local-file:///var/storage/secattach/20260831/27004158.html

Abbott launches whole milk ready-to-feed infant formula in the U.S.

Mon, 31 Aug 2026 08:01:18 -0400

Abbott (NYSE: ABT) has launched Similac 360 Total Care Made With Whole Milk, which the company claims is the first commercially sterile, ready-to-feed liquid infant formula made with whole milk available in the United States.

The product is available in 8 fl oz and 32 fl oz sizes and is priced at a per-feeding cost similar to Abbott's existing Similac 360 Total Care powdered infant formulas. Liquid infant formulas typically carry a higher price than powdered alternatives.

The formula contains whole milk and a blend of five human milk oligosaccharides, which are prebiotics. Abbott states the product does not contain corn syrup,

Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula

Mon, 31 Aug 2026 08:00:00 -0400

New Similac 360 Total Care Made With Whole Milk combines creamy whole milk for a fat blend that more closely resembles the fats in breast milk and five immune-nourishing prebiotics to help support baby's natural defenses—making it Similac's closest formula to breast milk
Abbott's liquid-only launch reflects growing parent interest in infant formulas made with whole milk while offering the convenience and reassurance that comes with commercially sterile, ready-to-feed formula
Product is available at prices similar to the per-feeding cost of powdered Similac 360 Total Care and is available online and at major U.S. retailers

ABBOTT PARK,

Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula

Mon, 31 Aug 2026 08:00:00 -0400

New Similac 360 Total Care Made With Whole Milk combines creamy whole milk for a fat blend that more closely resembles the fats in breast milk and five immune-nourishing prebiotics to help support baby's natural defenses—making it Similac's closest formula to breast milk
Abbott's liquid-only launch reflects growing parent interest in infant formulas made with whole milk while offering the convenience and reassurance that comes with commercially sterile, ready-to-feed formula
Product is available at prices similar to the per-feeding cost of powdered Similac 360 Total Care and is available online and at major U.S. retailers

ABBOTT PARK,

Form 4 ABBOTT LABORATORIES For: Aug 25 Filed by: Ford Robert B

Thu, 27 Aug 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260827/26991147.html

Form 4 ABBOTT LABORATORIES For: Aug 25 Filed by: Ford Robert B

Thu, 27 Aug 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260827/26991147.html

Abbott wins CE Mark for Amulet 360 heart device in Europe

Thu, 27 Aug 2026 09:00:59 -0400

Abbott (NYSE: ABT) has received CE Mark approval for its Amulet 360 Left Atrial Appendage (LAA) Occluder, a device designed to reduce stroke risk in patients with non-valvular atrial fibrillation (AFib), according to a company statement.

The device seals the left atrial appendage, a small pouch in the heart's upper left chamber where blood clots commonly form in AFib patients. It is intended as an alternative for patients who cannot tolerate long-term blood-thinning medication.

Following approval, the first European procedures using Amulet 360 were performed at three sites: the Cardiovascular Clinic Bethanien in Frankfurt, Germany; the University Heart Center in Lubeck, Germany;

Abbott wins CE Mark for Amulet 360 heart device in Europe

Thu, 27 Aug 2026 09:00:59 -0400

Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke

Thu, 27 Aug 2026 09:00:00 -0400

Amulet 360 helps seal the left atrial appendage (LAA) of a person's heart, reducing the need for blood-thinning medication
Amulet 360 builds upon Abbott's first-generation LAA device with design updates to enhance how the implant conforms to and seals the LAA to help reduce the risk of a stroke
Recent clinical trial data show Amulet 360 met benchmarks for safety and effectiveness

ABBOTT PARK, Ill., Aug. 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced today it has received CE Mark for the Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce risk

Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke

Thu, 27 Aug 2026 09:00:00 -0400

Amulet 360 helps seal the left atrial appendage (LAA) of a person's heart, reducing the need for blood-thinning medication
Amulet 360 builds upon Abbott's first-generation LAA device with design updates to enhance how the implant conforms to and seals the LAA to help reduce the risk of a stroke
Recent clinical trial data show Amulet 360 met benchmarks for safety and effectiveness

Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke

Thu, 27 Aug 2026 09:00:00 -0400

Amulet 360 helps seal the left atrial appendage (LAA) of a person's heart, reducing the need for blood-thinning medication
Amulet 360 builds upon Abbott's first-generation LAA device with design updates to enhance how the implant conforms to and seals the LAA to help reduce the risk of a stroke
Recent clinical trial data show Amulet 360 met benchmarks for safety and effectiveness